Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
arqt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Arcutis Biotherapeutics, Inc. (ARQT) measures how much investors pay for each dollar of the company's trailing earnings. ARQT's current PE ratio of N/A is calculated by dividing its stock price of $21.54 by its TTM earnings per share of -$0.02.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Arcutis Biotherapeutics, Inc.You ARQT | $2.7B | N/A | — | -$0.02 |
 Celcuity Inc. CELC | $4.3B | N/A | — | -$3.37 |
 CG Oncology, Inc. Common stock CGON | $4.8B | N/A | — | -$2.08 |
 Centessa Pharmaceuticals plc CNTA | $6.1B | N/A | — | -$1.46 |
 Amicus Therapeutics, Inc. FOLD | $4.5B | N/A | — | -$0.09 |
 Disc Medicine, Inc. IRON | $2.5B | N/A | — | -$6.01 |
 Legend Biotech Corporation LEGN | $5.8B | N/A | — | -$1.61 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.13 | — | |
2024-12-31 FY2024 | — | $-1.16 | — | |
2023-12-31 FY2023 | — | $-3.78 | — | |
2022-12-31 FY2022 | — | $-5.66 | — | |
2021-12-31 FY2021 | — | $-4.18 | — | |
2020-12-31 FY2020 | — | $-3.80 | — | |
2019-12-31 FY2019 | — | $-1.10 | — | |
2018-12-31 FY2018 | — | $-0.53 | — | |
2017-12-31 FY2017 | — | $-4.71 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Arcutis Biotherapeutics, Inc. (ARQT) measures how much investors pay for each dollar of the company's trailing earnings. ARQT's current PE ratio of N/A is calculated by dividing its stock price of $21.54 by its TTM earnings per share of -$0.02.
Frequently asked questions
ARQT pe ratio · 6 questionsARQT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $21.54 and TTM EPS of -$0.02. Data sourced from Financial Modeling Prep via ARQT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Arcutis Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08